Clinical Trial

Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

Name: Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer — clinical trial record (NCT07180056)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

To evaluate the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-09-11.

Status change: Not Yet Recruiting → Recruiting 2025-11-16

Trial Details

NCT Number	NCT07180056
Lead Sponsor	Wenjin Yin
Conditions	Breast Cancer
Enrollment	229 participants
Start Date	2025-08-28
Primary Completion	2028-02 (estimated)
Study Completion	2033-02 (estimated)
Updated on ClinicalTrials.gov	2025-11-19